The FDA issued a Complete Response Letter citing deficiencies previously identified at a third-party manufacturing vendor, indicating unresolved manufacturing/quality issues. The company also notes that an FDA inspection of the third-party facility did not occur during the NDA resubmission review, adding uncertainty around timing for resolution. Overall, the update is a setback that may delay approval progress and future product commercialization.
The FDA issued a Complete Response Letter citing deficiencies previously identified at a third-party manufacturing vendor, indicating unresolved manufacturing/quality issues. The company also notes that an FDA inspection of the third-party facility did not occur during the NDA resubmission review, adding uncertainty around timing for resolution. Overall, the update is a setback that may delay approval progress and future product commercialization.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
moderately negative
Sentiment Score
-0.45
